Comparison

Anti-ACE2 (NT) - 0.1 mg

Item no. LEIN-A316-0.1mg
Manufacturer Leinco Technologies
Amount 0.1 mg
Quantity options 0.1 mg 20 ug
Category
Type Antibody Primary
Applications WB, IF, IHC, ELISA
Specific against Human (Homo sapiens), Mouse (Murine, Mus musculus), Rat (Rattus norvegicus)
Host Rabbit
ECLASS 10.1 32160702
ECLASS 11.0 32160702
UNSPSC 12352203
Shipping Condition Room temperature
Available
Manufacturer - Applications
ELISA, IF, IHC FFPE, WB
Manufacturer - Category
Polyclonal Antibodies|SARS-CoV-2
Manufacturer - Targets
ACE2
Country of Origin
USA
Shipping Temperature
Next Day Ambient
Storage Conditions
This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at –20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Product Description
Angiotensin I converting enzyme 2 (ACE2) is an exopeptidase that catalyses the conversion of angiotensin I to the nonapeptide angiotensin, or the conversion of angiotensin II to angiotensin. ACE 2 has direct effects on cardiac function, and is expressed predominantly in vascular endothelial cells of the heart and the kidneys. ACE2 plays a regulatory role in lung pathophysiology, including pulmonary fibrosis and acute lung disease. Activation of ACE2 by a small molecule can be a therapeutically relevant approach for treating and controlling Pulmonary Hypertension (PH). ACE2 may also have clinical potential as a novel molecular target for the treatment of pancreatic ductal adenocarcinoma (PDAC).
Background
Angiotensin I converting enzyme 2 (ACE2) is an exopeptidase that catalyses the conversion of angiotensin I to the nonapeptide angiotensin, or the conversion of angiotensin II to angiotensin. ACE 2 has direct effects on cardiac function, and is expressed predominantly in vascular endothelial cells of the heart and the kidneys. ACE2 plays a regulatory role in lung pathophysiology, including pulmonary fibrosis and acute lung disease. Activation of ACE2 by a small molecule can be a therapeutically relevant approach for treating and controlling Pulmonary Hypertension (PH). ACE2 may also have clinical potential as a novel molecular target for the treatment of pancreatic ductal adenocarcinoma (PDAC).
PubMed
ACE2
Manufacturer - Research Area
COVID-19, Viral
Manufacturer - Specificity
Rabbit Anti-Human Angiotensin-Converting Enzyme 2 (ACE2) recognizes an epitope near the N-terminus of Human ACE2. This polyclonal antibody was purified using affinity chromatography.
RRID
AB_2828100
Concentration
1.0 mg/ml
Formulation
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Immunogen
Anti-ACE2 antibody was raised against a peptide corresponding to 14 amino acids near the amino terminus of human ACE2. The immunogen is located within the first 50 amino acids of ACE2.
Additional Information
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Keywords
Polyclonal Antibody, Angiotensin-Converting Enzyme 2, ACEH, ACE2, Human, Anti-Human Angiotensin-Converting Enzyme 2 (NT), ACE2 Antibody, ACEH, Angiotensin-converting enzyme 2, ACE-related carboxypeptidase, ACEH, SARS-CoV-2 receptor, COVID-19

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 0.1 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close